Clinical Trials Browser

Completed × Sarcoma, Synovial × cixutumumab × Clear all

Leiomyosarcoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Sarcoma, Synovial, Neuroectodermal Tumors, Primitive, Peripheral, Neuroectodermal Tumors, Primitive

NCT00720174 2016-05-17

Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma

Phase 1 Completed

30 enrolled

Sarcoma

Malignant mesenchymal tumor, Hemangiopericytoma, Malignant, Chondrosarcoma, Extraskeletal Myxoid, Fibrosarcoma, Hemangiosarcoma, Leiomyosarcoma, Liposarcoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Synovial, Dermatofibrosarcoma, Neurofibrosarcoma, Histiocytoma, Malignant Fibrous, Desmoplastic Small Round Cell Tumor

NCT00831844 2015-03-30

Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors

Phase 2 Completed

116 enrolled 8 charts

CNSEndocrineGastrointestinalGenitourinaryOther solid neoplasmSarcoma

Wilms Tumor, Neuroblastoma, Retinoblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Sarcoma, Synovial, Neuroectodermal Tumors, Hepatoblastoma, Adrenocortical Carcinoma

Clinical Trials

A Five-Tier, Open-Label Study of IMC-A12 in Advanced Sarcoma

Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma

Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors